Angene Chemical
Draw
|
Currency :
Home Products

AG005IU1

75706-12-6 | Leflunomide

Chemical structure of Leflunomide, CAS 75706-12-6
AG005IU1
sdsSDS
sdsCOA

Price

$0.00

Add to Cart
WARNING This product is not for human or veterinary use.
Request For Quotation
CAS Number 75706-12-6
Catalog Number AG005IU1(AGN-PC-07A21Q)
Chemical Name Leflunomide
IUPAC Name 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
InChI InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
InChI Key VHOGYURTWQBHIL-UHFFFAOYSA-N
MDL Number MFCD00867593
Molecular Formula C12H9F3N2O2
Molecular Weight 270.2073
SMILES O=C(C1=C(C)ON=C1)NC2=CC=C(C(F)(F)F)C=C2
UNII G162GK9U4W
Synonyms
Arava, HWA 486, HWA-486, HWA486, leflunomide, N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide, SU101, leflunomide, 75706-12-6, Arava, Leflunomidum, lefunamide, Leflunomida, HWA 486, Leflunomidum [INN-Latin], HWA-486, 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide, Leflunomida [INN-Spanish], SU 101 (pharmaceutical), Arava (TN), Lefunomide [Inn-Spanish], SU101, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide, 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide, UNII-G162GK9U4W, SU-101, 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide, 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-, alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide, HSDB 7289, CHEMBL960, RS-34821, MLS000069648, CHEBI:6402, G162GK9U4W, N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide, 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide), MFCD00867593, NCGC00015610-02, SMR000058209, 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-, CAS-75706-12-6, DSSTox_CID_3201, DSSTox_RID_76923, DSSTox_GSID_23201, Leflunomid, Repso, Leflunomide [USAN:INN], SR-01000000191, Lefunomide, Arabloc, Leflunomide (JAN/USAN/INN), HWA486, Prestwick_87, Leflunomide [USAN:USP:INN:BAN], SU 101, SULOL, N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide, Spectrum_000322, AC1L1GYK, AC1Q2EVA, Opera_ID_1709, Prestwick0_000772, Prestwick1_000772, Prestwick2_000772, Prestwick3_000772, Spectrum5_000850, Lopac-L-5025, L 5025, SCHEMBL5057, BIDD:PXR0189, Lopac0_000649, BSPBio_000844, KBioSS_000802, Leflunomide, Immunosuppressant, MLS001076267, DivK1c_000916, SPECTRUM1503927, 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide, SPBio_002783, BPBio1_000930, GTPL6825, ISO054, ZINC4840, DTXSID9023201, CTK8G0535, HMS502N18, KBio1_000916, KBio2_000802, KBio2_003370, KBio2_005938, KS-00000KQI, AOB5964, NINDS_000916, VHOGYURTWQBHIL-UHFFFAOYSA-N, 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl, 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl), 5-methyl-n-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamid, HMS1570K06, HMS1922M06, HMS2090O12, HMS2097K06, HMS2235C07, HMS3262A19, HMS3268D12, HMS3371F21, HMS3654F07, HMS3678N21, HMS3714K06, Pharmakon1600-01503927, ALBB-019233, BCP22241, EBD46417, HY-B0083, Tox21_110182, Tox21_301873, Tox21_500649, ABP001076, BDBM50054601, DL-433, NSC677411, NSC759864, s1247, STL426823, AKOS000265193, Tox21_110182_1, AC-6796, AN-9632, BCP9000846, CCG-204736, CS-1781, DB01097, KS-1076, LP00649, MCULE-9490869974, NSC-677411, NSC-759864, RP29613, SB17287, IDI1_000916, NCGC00015610-01, NCGC00015610-03, NCGC00015610-04, NCGC00015610-05, NCGC00015610-06, NCGC00015610-07, NCGC00015610-08, NCGC00015610-09, NCGC00015610-10, NCGC00015610-11, NCGC00015610-12, NCGC00015610-13, NCGC00015610-14, NCGC00015610-17, NCGC00015610-18, NCGC00022625-03, NCGC00022625-04, NCGC00022625-05, NCGC00022625-06, NCGC00022625-07, NCGC00022625-08, NCGC00255370-01, NCGC00261334-01, AJ-08231, AK161855, BC204155, H527, LS-86580, SC-46541, ST079287, ZB000596, AB0007396, TL8005179, A9622, AB00052389, EU-0100649, FT-0621959, L0250, R3926, ST24047486, SW196399-3, C07905, D00749, MLS-0003109.0001, AB00052389-17, AB00052389-18, AB00052389_19, AB00052389_21, 706L126, A77 1486, I06-2131, Q-201289, SR-01000000191-2, SR-01000000191-4, SR-01000000191-7, BRD-K78692225-001-03-9, BRD-K78692225-001-11-2, 5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole, 5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole, 5-METHYLISOXAZOLE-4-(4-TRIFLUOROMETHYLCARBOXANILID, Leflunomide, European Pharmacopoeia (EP) Reference Standard, N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide;, 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide, N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide, (5-methylisoxazol-4-yl)-N-[4-(trifluoromethyl)phenyl]carboxamide, Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-, Leflunomide, United States Pharmacopeia (USP) Reference Standard, Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material, Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard, avara, lefumide, leflunomide medac, Leflunomide Apotex, Arava, Leflunomide, Leflunomide Actavis, Leflunomide [INN], C12H9F3N2O2, D08ROP, Aventis Brand of Leflunomide, Hoechst Brand of Leflunomide, Leflunomide, 98% - 1g 1g, CID3899, Aventis Pharma Brand of Leflunomide, Aventis Behring Brand of Leflunomide, C12-H9-F3-N2-O2, CL0019, CS-O-01811, A2852, A10521, AP-501/42475599, C045463, D000077339, 4-Isoxazolecarboxamida, 5-metil-N-[4-(trifluorometil)fenil]-,

Related Research Chemicals

    CERTIFICATE OF ANALYSIS
    Chemical Name: Batch Number:
    Chemical Structure: CAS Registry No:
    		Product ID:
    Manufacture Date:
    Storage Temperature:
    Formula:
    Molecular Weight:
    Quantity:
    Analysis Data:
    Test: Result:
    Conclusion: The above product meets the specifications of Angene.
    Analyst:Chase
    Date:
    Reviewed by:Jessie
    Date:
    Angene International Limited